PT2640358T - Administração contínua de l-dopa, inibidores de dopa descarboxilase, inibidores de catecol-o-metil transferase e composições para os mesmos - Google Patents
Administração contínua de l-dopa, inibidores de dopa descarboxilase, inibidores de catecol-o-metil transferase e composições para os mesmosInfo
- Publication number
- PT2640358T PT2640358T PT118083591T PT11808359T PT2640358T PT 2640358 T PT2640358 T PT 2640358T PT 118083591 T PT118083591 T PT 118083591T PT 11808359 T PT11808359 T PT 11808359T PT 2640358 T PT2640358 T PT 2640358T
- Authority
- PT
- Portugal
- Prior art keywords
- dopa
- inhibitors
- catechol
- compositions
- same
- Prior art date
Links
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 title 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 title 1
- 239000003543 catechol methyltransferase inhibitor Substances 0.000 title 1
- 239000000534 dopa decarboxylase inhibitor Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Psychology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41363710P | 2010-11-15 | 2010-11-15 | |
| US201161524064P | 2011-08-16 | 2011-08-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2640358T true PT2640358T (pt) | 2018-02-23 |
Family
ID=45478410
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT172077315T PT3326615T (pt) | 2010-11-15 | 2011-11-15 | Administração continua de l-dopa, inibidores de dopa descarboxilase, inibidores de catecol-o-metil transferase e composições para os mesmos |
| PT118083591T PT2640358T (pt) | 2010-11-15 | 2011-11-15 | Administração contínua de l-dopa, inibidores de dopa descarboxilase, inibidores de catecol-o-metil transferase e composições para os mesmos |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT172077315T PT3326615T (pt) | 2010-11-15 | 2011-11-15 | Administração continua de l-dopa, inibidores de dopa descarboxilase, inibidores de catecol-o-metil transferase e composições para os mesmos |
Country Status (27)
| Country | Link |
|---|---|
| US (6) | US9421267B2 (pt) |
| EP (3) | EP2640358B1 (pt) |
| JP (3) | JP5902705B2 (pt) |
| KR (1) | KR101859242B1 (pt) |
| CN (2) | CN110123743A (pt) |
| AU (1) | AU2011330757B2 (pt) |
| BR (1) | BR112013011685B1 (pt) |
| CA (1) | CA2817888C (pt) |
| CL (1) | CL2013001368A1 (pt) |
| CY (1) | CY1120005T1 (pt) |
| DK (2) | DK2640358T3 (pt) |
| ES (2) | ES2660772T3 (pt) |
| HR (2) | HRP20180514T1 (pt) |
| HU (2) | HUE037005T2 (pt) |
| IL (1) | IL263954A (pt) |
| LT (1) | LT2640358T (pt) |
| MX (1) | MX348225B (pt) |
| NZ (1) | NZ610911A (pt) |
| PL (2) | PL3326615T3 (pt) |
| PT (2) | PT3326615T (pt) |
| RS (1) | RS57047B1 (pt) |
| RU (2) | RU2607497C2 (pt) |
| SG (2) | SG190258A1 (pt) |
| SI (1) | SI2640358T1 (pt) |
| SM (1) | SMT201800145T1 (pt) |
| WO (1) | WO2012066538A1 (pt) |
| ZA (1) | ZA201303509B (pt) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010134074A1 (en) | 2009-05-19 | 2010-11-25 | Neuroderm Ltd | Compositions for continuous administration of dopa decarboxylase inhibitors |
| DK2640370T3 (en) | 2010-11-15 | 2018-06-25 | Neuroderm Ltd | COMPOSITIONS FOR TRANSDERMAL DELIVERY OF ACTIVE RESOURCES |
| RS57047B1 (sr) | 2010-11-15 | 2018-05-31 | Neuroderm Ltd | Neprekidno davanje l dope, inhibitora dopa dekarboksilaze, inhibitora katehol-o-metil transferaze i kompozicije za iste |
| CN104349768B (zh) | 2012-06-05 | 2017-11-07 | 纽罗德姆有限公司 | 包含阿朴吗啡和有机酸的组合物及其用途 |
| BR112015022390A8 (pt) * | 2013-03-13 | 2019-11-26 | Neuroderm Ltd | uso de carbidopa, levodopa e um inibidor de comt para a preparação de uma composição para tratamento de doença de parkinson |
| JP6528281B2 (ja) * | 2014-01-29 | 2019-06-12 | 国立研究開発法人産業技術総合研究所 | シクロデキストリンの利用による抗がん活性が増強されたアシュワガンダ葉の水抽出物の調製方法、及びアシュワガンダ葉を含む医薬組成物 |
| US10258585B2 (en) | 2014-03-13 | 2019-04-16 | Neuroderm, Ltd. | DOPA decarboxylase inhibitor compositions |
| WO2015136538A1 (en) * | 2014-03-13 | 2015-09-17 | Neuroderm Ltd | Dopa decarboxylase inhibitor compositions |
| CA3175785A1 (en) | 2014-09-04 | 2016-03-10 | Intrance International Ab | Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a comt inhibitor and method of administration thereof |
| MX2017005236A (es) | 2014-10-21 | 2017-07-26 | Abbvie Inc | Profarmacos de carbidopa y l-dopa y metodos de uso. |
| MA41377A (fr) * | 2015-01-20 | 2017-11-28 | Abbvie Inc | Gel intestinal de lévodopa et de carbidona et procédés d'utilisation |
| DK3075723T3 (en) | 2015-03-30 | 2017-09-11 | Berlirem Gmbh | High-resolution L-DOPA glycerol esters |
| EP3277660B1 (en) | 2015-03-30 | 2019-10-16 | Berlirem GmbH | Water-soluble l-dopa esters |
| BR112017023674A2 (pt) | 2015-05-06 | 2018-07-17 | Synagile Corporation | suspensões farmacêuticas contendo partículas de fármaco, dispositivos para sua administração, e métodos de seu uso |
| WO2017039525A1 (en) * | 2015-09-04 | 2017-03-09 | Lobsor Pharmaceuticals Aktiebolag | Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor |
| US20190224220A1 (en) * | 2016-04-20 | 2019-07-25 | Abbvie Inc. | Carbidopa and L-Dopa Prodrugs and Methods of Use |
| EP3275433A1 (en) * | 2016-07-29 | 2018-01-31 | Som Innovation Biotech S.L. | Sustained release composition comprising micronized tolcapone |
| CN106619490A (zh) * | 2017-01-19 | 2017-05-10 | 云南白药集团无锡药业有限公司 | 一种左旋多巴透皮贴剂及其制备方法 |
| CA3065990A1 (en) * | 2017-06-05 | 2018-12-13 | Dizlin Pharmaceuticals Ab | Levodopa infusion solution |
| AU2018295533B2 (en) | 2017-07-07 | 2021-07-22 | Neuroderm Ltd | Device for subcutaneous delivery of fluid medicament |
| AU2019237857B2 (en) | 2018-03-23 | 2024-11-21 | Lobsor Pharmaceuticals Aktiebolag | Continuous administration of pharmaceutical composition for treatment of neurodegenerative disorders |
| WO2020102628A1 (en) | 2018-11-15 | 2020-05-22 | Abbvie Inc. | Pharmaceutical formulations for subcutaneous administration |
| CN111701024B (zh) * | 2020-05-26 | 2022-05-24 | 上海京新生物医药有限公司 | 一种左旋多巴制剂及其制备方法及其应用 |
| CN111643493B (zh) * | 2020-05-26 | 2023-01-10 | 上海京新生物医药有限公司 | 一种高浓度左旋多巴制剂及其制备方法及其应用 |
| US20230181508A1 (en) * | 2020-08-31 | 2023-06-15 | Purdue Pharma L.P. | Compositions and methods for levodopa delivery |
| US11331293B1 (en) | 2020-11-17 | 2022-05-17 | Neuroderm, Ltd. | Method for treatment of Parkinson's disease |
| US11213502B1 (en) * | 2020-11-17 | 2022-01-04 | Neuroderm, Ltd. | Method for treatment of parkinson's disease |
| US11844754B2 (en) | 2020-11-17 | 2023-12-19 | Neuroderm, Ltd. | Methods for treatment of Parkinson's disease |
| KR20240131429A (ko) * | 2022-01-03 | 2024-08-30 | 뉴로덤 엘티디 | 파킨슨병을 치료하기 위한 방법 및 조성물 |
| EP4223288B1 (en) | 2022-02-07 | 2024-03-06 | Berlirem GmbH | Novel kit of pharmaceutical preparations for the treatment of parkinson's disease |
| US12161612B2 (en) | 2023-04-14 | 2024-12-10 | Neuroderm, Ltd. | Methods and compositions for reducing symptoms of Parkinson's disease |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3808317A (en) * | 1969-10-29 | 1974-04-30 | Alcon Labor Inc | Stabilized aqueous borate complexes of biologically active catechol amines |
| US3936495A (en) | 1973-11-27 | 1976-02-03 | Merck & Co., Inc. | Purification process |
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4241082A (en) | 1977-09-02 | 1980-12-23 | Sankyo Company Limited | Agents for promoting reproductive ability of domestic animals |
| JPS5450700A (en) | 1977-09-28 | 1979-04-20 | Sankyo Co | Glazing agent of animal leather |
| JPS6021570B2 (ja) * | 1978-07-04 | 1985-05-28 | 三共株式会社 | ド−パ類の高濃度製剤の製法 |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| US4642316A (en) | 1985-05-20 | 1987-02-10 | Warner-Lambert Company | Parenteral phenytoin preparations |
| DE3779500T2 (de) | 1986-06-10 | 1993-01-21 | Chiesi Farma Spa | Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen. |
| US4684666A (en) | 1986-08-19 | 1987-08-04 | Haas Pharmaceuticals, Inc. | Stabilized liquid analgesic compositions |
| US4963568A (en) * | 1989-05-31 | 1990-10-16 | Abbott Laboratories | Dopamine agonists |
| CA2058975C (en) | 1990-10-30 | 2000-06-06 | Shuichi Kasai | Antiinflammatory gel preparation |
| US5877176A (en) | 1991-12-26 | 1999-03-02 | Cornell Research Foundation, Inc. | Blocking induction of tetrahydrobiopterin to block induction of nitric oxide synthesis |
| GB9523833D0 (en) * | 1995-11-22 | 1996-01-24 | Boots Co Plc | Medical treatment |
| IL119417A (en) * | 1996-10-13 | 2003-02-12 | Moshe Kushnir | Pharmaceutical composition for transdermal administration of levodopa for parkinson's disease |
| US5861423A (en) | 1997-02-21 | 1999-01-19 | Caldwell; William Scott | Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds |
| US6245917B1 (en) | 1998-03-20 | 2001-06-12 | Warner-Lambert Company | Crystalline sodium phenytoin monohydrate |
| US7201923B1 (en) | 1998-03-23 | 2007-04-10 | General Mills, Inc. | Encapsulation of sensitive liquid components into a matrix to obtain discrete shelf-stable particles |
| IL139298A0 (en) | 1998-05-15 | 2001-11-25 | Warner Lambert Co | Stabilized pharmaceutical preparations of gamma-aminobutyric acid derivatives and process for preparing the same |
| US6274168B1 (en) | 1999-02-23 | 2001-08-14 | Mylan Pharmaceuticals Inc. | Phenytoin sodium pharmaceutical compositions |
| US6716452B1 (en) | 2000-08-22 | 2004-04-06 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
| AU3490300A (en) | 1999-03-12 | 2000-10-04 | Nitromed, Inc. | Dopamine agonists in combination with nitric oxide donors, compositions and methods of use |
| FI109453B (fi) | 1999-06-30 | 2002-08-15 | Orion Yhtymae Oyj | Farmaseuttinen koostumus |
| US7479498B2 (en) | 1999-08-23 | 2009-01-20 | Phoenix Biosciences, Inc. | Treatments for viral infections |
| US6348965B1 (en) | 1999-09-24 | 2002-02-19 | Henry Palladino | Solid state fluorescence and absorption spectroscopy |
| SE0001151D0 (sv) | 2000-03-31 | 2000-03-31 | Amarin Dev Ab | Method for producing a controlled-release composition |
| US20020028799A1 (en) | 2000-07-06 | 2002-03-07 | Naylor Alasdair Mark | Treatment of male sexual dysfunction |
| GB0017387D0 (en) | 2000-07-14 | 2000-08-30 | Pfizer Ltd | Novel enzyme |
| US20020099013A1 (en) | 2000-11-14 | 2002-07-25 | Thomas Piccariello | Active agent delivery systems and methods for protecting and administering active agents |
| US20030119714A1 (en) | 2000-12-15 | 2003-06-26 | Naylor Alasdair Mark | Treatment of male sexual dysfunction |
| EP1347750A1 (en) * | 2000-12-15 | 2003-10-01 | Pfizer Limited | Treatment of male sexual dysfunction |
| WO2003050261A2 (en) | 2001-12-10 | 2003-06-19 | Bristol-Myers Squibb Company | (1-phenyl-2-heteroaryl)ethyl-guanidine compounds as inhibitors of mitochondrial f1f0 atp hydrolase |
| MXPA04009906A (es) | 2002-04-11 | 2004-12-13 | Ranbaxy Lab Ltd | Composiciones farmaceuticas de liberacion controlada de carbipoda y levopoda. |
| US7985422B2 (en) | 2002-08-05 | 2011-07-26 | Torrent Pharmaceuticals Limited | Dosage form |
| AU2003301414B8 (en) * | 2002-10-10 | 2010-06-17 | Morphochem Aktiengesellschaft Fur Kombinatorische Chemie | Novel compounds with antibacterial activity |
| DE10247233A1 (de) * | 2002-10-10 | 2004-06-17 | Morphochem AG Aktiengesellschaft für kombinatorische Chemie | Neue Verbindungen, die Topoisomerase IV inhibieren |
| KR101137785B1 (ko) | 2003-07-18 | 2012-04-25 | 백스터 인터내셔널 인코포레이티드 | 제어된 상 분리에 의해 제조된 작은 구형 입자의 제조방법, 이용 방법 및 조성물 |
| US8173840B2 (en) | 2003-07-29 | 2012-05-08 | Signature R&D Holdings, Llc | Compounds with high therapeutic index |
| US7589233B2 (en) | 2003-07-29 | 2009-09-15 | Signature R&D Holdings, Llc | L-Threonine derivatives of high therapeutic index |
| GB0319935D0 (en) | 2003-08-26 | 2003-09-24 | Cipla Ltd | Polymorphs |
| US20050053669A1 (en) * | 2003-09-05 | 2005-03-10 | Boehringer Ingelheim International Gmbh | Administration form for the oral application of poorly soluble acidic and amphorteric drugs |
| KR20060123219A (ko) | 2003-10-31 | 2006-12-01 | 알자 코포레이션 | 레보도파 및 카르비도파의 투여 |
| WO2005099678A1 (en) * | 2004-04-06 | 2005-10-27 | Transform Pharmaceuticals, Inc. | Pharmaceutical compositions and method of using levodopa and carbidopa |
| SE0401842D0 (sv) * | 2004-07-12 | 2004-07-12 | Dizlin Medical Design Ab | Infusion and injection solution of levodopa |
| DK1797109T3 (en) | 2004-09-09 | 2016-04-11 | Yeda Res & Dev | MIXTURES OF POLYPEPTIDES, compositions containing them and methods for their preparation, and uses thereof |
| WO2006037061A2 (en) | 2004-09-28 | 2006-04-06 | Farouk Karoum | Compositions and methods of using d-dopa to treat parkinson's disease |
| AU2005292184A1 (en) * | 2004-10-01 | 2006-04-13 | The Research Foundation Of State University Of New York | Morphine and morphine precursors |
| DE102006021872B4 (de) * | 2006-05-11 | 2008-04-17 | Sanofi-Aventis | 4,5-Diphenyl-pyrimidinyl-oxy oder -mercapto substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| KR20090057349A (ko) * | 2006-05-31 | 2009-06-05 | 솔베이 파머슈티컬스 게엠베하 | 레보도파／칼비도파의 ２４시간의 장기간 장내투여 |
| US8058243B2 (en) | 2006-10-13 | 2011-11-15 | Hsc Research And Development Limited Partnership | Method for treating a brain cancer with ifenprodil |
| JP5631734B2 (ja) | 2007-04-06 | 2014-11-26 | トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド | 流体薬物を供給するためのシステム及び方法 |
| CN101669925B (zh) | 2008-09-10 | 2011-08-10 | 天津药物研究院 | 干粉吸入剂、其制备方法和用途 |
| US20130253056A1 (en) | 2009-05-19 | 2013-09-26 | Neuroderm, Ltd. | Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same |
| WO2010134074A1 (en) | 2009-05-19 | 2010-11-25 | Neuroderm Ltd | Compositions for continuous administration of dopa decarboxylase inhibitors |
| CN101987081B (zh) | 2010-07-16 | 2012-08-08 | 钟术光 | 一种控释制剂 |
| KR101187064B1 (ko) | 2010-07-18 | 2012-09-28 | 주식회사 바이오폴리메드 | 양이온성 지질, 이의 제조 방법 및 이를 포함하는 세포내 이행성을 갖는 전달체 |
| US10150792B2 (en) | 2010-11-08 | 2018-12-11 | Synthonics, Inc. | Bismuth-containing compounds, coordination polymers, methods for modulating pharmacokinetic properties of biologically active agents, and methods for treating patients |
| DK2640370T3 (en) | 2010-11-15 | 2018-06-25 | Neuroderm Ltd | COMPOSITIONS FOR TRANSDERMAL DELIVERY OF ACTIVE RESOURCES |
| RS57047B1 (sr) | 2010-11-15 | 2018-05-31 | Neuroderm Ltd | Neprekidno davanje l dope, inhibitora dopa dekarboksilaze, inhibitora katehol-o-metil transferaze i kompozicije za iste |
| SG191090A1 (en) | 2010-12-10 | 2013-07-31 | Synagile Corp | Subcutaneously infusible levodopa prodrug compositions and methods of infusion |
| US20130116215A1 (en) | 2011-10-28 | 2013-05-09 | Mireia Coma | Combination therapies for treating neurological disorders |
| BR112015022390A8 (pt) | 2013-03-13 | 2019-11-26 | Neuroderm Ltd | uso de carbidopa, levodopa e um inibidor de comt para a preparação de uma composição para tratamento de doença de parkinson |
| WO2015136538A1 (en) | 2014-03-13 | 2015-09-17 | Neuroderm Ltd | Dopa decarboxylase inhibitor compositions |
-
2011
- 2011-11-15 RS RS20180386A patent/RS57047B1/sr unknown
- 2011-11-15 RU RU2013123457A patent/RU2607497C2/ru active
- 2011-11-15 SG SG2013036678A patent/SG190258A1/en unknown
- 2011-11-15 DK DK11808359.1T patent/DK2640358T3/en active
- 2011-11-15 CA CA2817888A patent/CA2817888C/en active Active
- 2011-11-15 KR KR1020137015306A patent/KR101859242B1/ko not_active Application Discontinuation
- 2011-11-15 WO PCT/IL2011/000881 patent/WO2012066538A1/en active Application Filing
- 2011-11-15 LT LTEP11808359.1T patent/LT2640358T/lt unknown
- 2011-11-15 SG SG10201509316SA patent/SG10201509316SA/en unknown
- 2011-11-15 BR BR112013011685-4A patent/BR112013011685B1/pt active IP Right Grant
- 2011-11-15 SI SI201131440T patent/SI2640358T1/en unknown
- 2011-11-15 JP JP2013538326A patent/JP5902705B2/ja active Active
- 2011-11-15 PT PT172077315T patent/PT3326615T/pt unknown
- 2011-11-15 AU AU2011330757A patent/AU2011330757B2/en active Active
- 2011-11-15 PL PL17207731T patent/PL3326615T3/pl unknown
- 2011-11-15 SM SM20180145T patent/SMT201800145T1/it unknown
- 2011-11-15 DK DK17207731.5T patent/DK3326615T3/da active
- 2011-11-15 EP EP11808359.1A patent/EP2640358B1/en active Active
- 2011-11-15 EP EP20150020.4A patent/EP3692982A1/en not_active Withdrawn
- 2011-11-15 RU RU2016147575A patent/RU2740080C2/ru active
- 2011-11-15 EP EP17207731.5A patent/EP3326615B1/en active Active
- 2011-11-15 HU HUE11808359A patent/HUE037005T2/hu unknown
- 2011-11-15 PL PL11808359T patent/PL2640358T3/pl unknown
- 2011-11-15 ES ES11808359.1T patent/ES2660772T3/es active Active
- 2011-11-15 HU HUE17207731A patent/HUE047841T2/hu unknown
- 2011-11-15 MX MX2013005493A patent/MX348225B/es active IP Right Grant
- 2011-11-15 ES ES17207731T patent/ES2776734T3/es active Active
- 2011-11-15 CN CN201910369050.XA patent/CN110123743A/zh active Pending
- 2011-11-15 CN CN2011800648945A patent/CN103442693A/zh active Pending
- 2011-11-15 PT PT118083591T patent/PT2640358T/pt unknown
- 2011-11-15 NZ NZ610911A patent/NZ610911A/en not_active IP Right Cessation
- 2011-11-15 US US13/885,518 patent/US9421267B2/en active Active
-
2013
- 2013-05-15 CL CL2013001368A patent/CL2013001368A1/es unknown
- 2013-05-30 ZA ZA2013/03509A patent/ZA201303509B/en unknown
-
2014
- 2014-04-02 US US14/243,638 patent/US9040578B2/en active Active
- 2014-04-02 US US14/243,625 patent/US9040577B2/en active Active
-
2016
- 2016-03-10 JP JP2016047187A patent/JP6231145B2/ja active Active
- 2016-07-13 US US15/209,423 patent/US20170157077A1/en not_active Abandoned
-
2017
- 2017-10-18 JP JP2017201780A patent/JP6387171B2/ja active Active
-
2018
- 2018-03-06 CY CY20181100276T patent/CY1120005T1/el unknown
- 2018-03-28 HR HRP20180514TT patent/HRP20180514T1/hr unknown
- 2018-12-24 IL IL263954A patent/IL263954A/en unknown
-
2020
- 2020-01-22 US US16/749,435 patent/US20200397730A1/en not_active Abandoned
- 2020-03-04 HR HRP20200366TT patent/HRP20200366T1/hr unknown
-
2022
- 2022-03-16 US US17/696,243 patent/US20230047523A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL263954A (en) | Continuous administration of l-dopa, dopa decarboxylase inhibitors, o-methyltransferase inhibitors, and pharmaceutical preparations that include them | |
| ZA201109037B (en) | Compositions for continuous administration of dopa decarboxylase inhibitors | |
| HK1246674A1 (zh) | 犬尿氨酸-3-單加氧酶抑制劑、藥物組合物及其使用方法 | |
| ZA201206223B (en) | Certain kynurenine-3-monooxygenase inhibitors,pharmaceutical compositions, and methods of use thereof | |
| HK1199726A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof -3- | |
| HK1162352A1 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof -3- | |
| HK1198619A1 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof -3- | |
| IL220863A (en) | Oxazole derivatives of kinase inhibitors, medicinal preparations containing them and their uses | |
| EP2534145A4 (en) | THERAPEUTIC METHODS AND COMPOSITIONS INVOLVING THE INHIBITION OF ALLOSTERIC KINASE | |
| HK1206264A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof -3- | |
| IL223865B (en) | Calcium salts of dihydroortate dehydrogenase inhibitors, preparations containing them and their uses | |
| IL226239B (en) | Continuous administration of l-dopa, dopa decarboxylase inhibitors, o-methyltransferase inhibitors, and pharmaceutical preparations that include them |